Biogen Inc (BIIB)
293.50
-22.88 -7.23%
NASDAQ
Apr 1, 16:59
Delayed 2m
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 14.38B |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 31.47 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | 5.888B |
| Profitability | |
| Gross Profit Margin (Quarterly) | 87.82% |
| Profit Margin (Quarterly) | 39.22% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0% |
| Price and Valuation | |
| Market Cap | 51.09B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 3.826 |
| PE Ratio | 9.326 |
| Price to Book Value | 3.829 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.4463 |
| Free Cash Flow (Quarterly) | 1.695B |
| Return on Equity | Upgrade |
View All BIIB News
News
-
WireHeadlineTime (ET)
-
Yahoo04/01 06:10
-
Yahoo03/31 14:18
-
PR Newswire03/31 09:31
-
Yahoo03/30 19:00
-
Yahoo03/30 18:47
-
Yahoo03/30 10:53
-
Yahoo03/30 10:14
-
Yahoo03/29 08:37
-
Yahoo03/27 10:27
-
Yahoo03/27 10:20
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 04/24/2020 08:00 EDT | Misc | Biogen Inc First Quarter Earnings Conference Call in 2020 |
| 04/24/2020 | Earnings | Biogen Inc First Quarter Earnings in 2020 Release |
| 02/06/2020 | Misc | Biogen Inc Annual Report for 2019 |
| 01/30/2020 08:00 EST | Misc | Biogen Inc Fourth Quarter Earnings Conference Call for 2019 |
| 01/30/2020 | Earnings | Biogen Inc Fourth Quarter Earnings in 2019 Release |
| 10/22/2019 08:00 EDT | Misc | Biogen Inc Third Quarter Earnings Conference Call for 2019 |
| 10/22/2019 | Earnings | Biogen Inc Third Quarter Earnings in 2019 Release |
| 07/23/2019 08:00 EDT | Misc | Biogen Inc Second Quarter Earnings Conference Call in 2019 |
| 07/23/2019 | Earnings | Biogen Inc Second Quarter Earnings in 2019 Release |
| 06/19/2019 09:00 EDT | Misc | Biogen Inc Annual General Meeting in 2018 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: http://www.biogen.com
- Investor Relations URL: https://www.biogen.com/en_us/investors.html
- HQ State/Province: Massachusetts
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Equity Style: Large Cap/Value
- Next Earnings Release: Apr. 24, 2020
- Last Earnings Release: Jan. 30, 2020
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 293.50 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| LMPFX | ClearBridge Aggressive Growth FI | 8.43% |
| IBB | iShares Nasdaq Biotechnology ETF | 7.58% |
| FBT | First Trust NYSE Arca Biotech ETF | 4.28% |
| VPMCX | Vanguard PRIMECAP Inv | 3.97% |
| VHCOX | Vanguard Capital Opportunity Inv | 3.30% |
| FBIOX | Fidelity® Select Biotechnology | 3.05% |
| MOAT | VanEck Vectors Morningstar Wide Moat ETF | 3.04% |
| VPCCX | Vanguard PRIMECAP Core Inv | 2.45% |
| XBI | SPDR® S&P Biotech ETF | 2.26% |
| VGHCX | Vanguard Health Care Inv | 1.94% |
| XLV | Health Care Select Sector SPDR® ETF | 1.72% |
| VHT | Vanguard Health Care ETF | 1.36% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- BIIB Tweets Stocktwits
Advertisement
